
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
RenovoRx Inc (RNXT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: RNXT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $5.5
1 Year Target Price $5.5
2 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.32% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.81M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 4 | Beta 1.32 | 52 Weeks Range 0.75 - 1.69 | Updated Date 06/30/2025 |
52 Weeks Range 0.75 - 1.69 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1578.68% |
Management Effectiveness
Return on Assets (TTM) -69.73% | Return on Equity (TTM) -136.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33244901 | Price to Sales(TTM) 195.05 |
Enterprise Value 33244901 | Price to Sales(TTM) 195.05 | ||
Enterprise Value to Revenue 138.52 | Enterprise Value to EBITDA -4.72 | Shares Outstanding 36572200 | Shares Floating 29603759 |
Shares Outstanding 36572200 | Shares Floating 29603759 | ||
Percent Insiders 4.42 | Percent Institutions 27.55 |
Analyst Ratings
Rating 2 | Target Price 5.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
RenovoRx Inc
Company Overview
History and Background
RenovoRx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative targeted therapies for the local treatment of solid tumors. Founded in 2009, it has focused on developing its proprietary RenovoCath delivery system for targeted intra-arterial delivery of therapeutics.
Core Business Areas
- Trans-Arterial Micro-Perfusion (TAMP) Therapy: RenovoRx's core business revolves around its TAMP therapy platform, which combines the RenovoCath delivery system with chemotherapeutics to target solid tumors directly. This technology is designed to improve drug delivery to the tumor while minimizing systemic toxicity.
Leadership and Structure
Shaun Bagai is the CEO. The company has a board of directors and a management team focused on clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- RenovoCath Delivery System: The RenovoCath is a proprietary micro-perfusion system used to deliver therapeutic agents directly to tumors via intra-arterial delivery. It is designed to enhance drug penetration and minimize systemic side effects. Market share data is not publicly available as it is still in development and clinical trial stages. Competitors: Boston Scientific, Medtronic in drug delivery technologies, but not specifically TAMP.
Market Dynamics
Industry Overview
The oncology market is large and growing, with increasing demand for targeted therapies that can improve patient outcomes while reducing side effects. Local drug delivery is an evolving field within oncology.
Positioning
RenovoRx is positioned as an innovator in the local drug delivery space, focusing on improving the effectiveness of chemotherapy by targeting tumors directly. Competitive advantages include its proprietary RenovoCath technology and its focus on TAMP therapy.
Total Addressable Market (TAM)
The TAM for local drug delivery in oncology is estimated to be billions of dollars, encompassing various solid tumor types. RenovoRx is positioned to capture a portion of this market with its RenovoCath technology, depending on clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary RenovoCath technology
- Focus on targeted drug delivery
- Potential for improved efficacy and reduced toxicity
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
- Small market capitalization
Opportunities
- Expansion into new tumor types
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Increased adoption of local drug delivery
Threats
- Competition from established drug delivery companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- BSX
- MDT
- Varian Medical Systems (VAR)
- Elekta (EKTAY)
Competitive Landscape
RenovoRx has a unique approach with TAMP and RenovoCath, but faces competition from established players in drug delivery and oncology. Success depends on demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is measured by progress in clinical trials and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approval of RenovoCath for specific indications, and commercialization efforts. Analyst estimates should be reviewed for specific revenue projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for pancreatic cancer and bile duct cancer, and securing additional funding to support these efforts.
Summary
RenovoRx is a clinical-stage biopharmaceutical company with a proprietary drug delivery system focused on targeted cancer therapies. Its success hinges on the outcomes of its clinical trials and its ability to secure regulatory approvals. The company faces challenges typical of early-stage biotechs, including limited resources and reliance on positive clinical data. While innovative, it will require careful management to navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- RenovoRx SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports (where available)
- Industry Reports on Oncology and Drug Delivery
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. The biotechnology industry is inherently risky, and investors should conduct thorough due diligence before making any investment decisions. Market share data are estimates based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RenovoRx Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, Secretary & Director Mr. Shaun R. Bagai | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://renovorx.com |
Full time employees 10 | Website https://renovorx.com |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.